Pracinostat

Research use only, not for human use.

Pracinostat (SB939) is a potent, orally active HDAC inhibitor that potently inhibits class I, II, and IV HDACsw with Ki of 15-100 nM, inhibits HDAC1 with IC50 of 77 nM.

Pracinostat (SB939) is a potent, orally active HDAC inhibitor that potently inhibits class I, II, and IV HDACsw with Ki of 15-100 nM, inhibits HDAC1 with IC50 of 77 nM; shows cellular potency against COLO 205 cells with IC50 of 0.56 uM; Pracinostat (SB939) is highly efficacious in in vivo tumor models (HCT-116, PC-3, A2780, MV4-11, Ramos), and has high and dose-proportional oral exposures and very good ADME, safety, and pharmaceutical properties; also is a potent inhibitor of the growth of Plasmodium falciparum asexual-stage parasites in vitro (IC50=100 to 200 nM), causing hyperacetylation of parasite histone and nonhistone proteins.Blood Cancer Phase 3 Clinical

SB939;SB-939;SB 939

Cell Cycle/DNA Damage

HDAC

HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC4;HDAC5;HDAC6;HDAC7;HDAC8;HDAC9

Cancer

Blood cancer

929016-96-6

358.48

C20H30N4O2

>98% (HPLC)

10 mM in DMSO

O=C(NO)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1

2-Propenamide, 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-, (2E)-

(-20℃)

With Ice Pack

≥ 2 years